Old asthma drug shows promise for rare genetic disorder

NCT ID NCT04240821

ENROLLING_BY_INVITATION Disease control Sponsor: Jaclyn Tamaroff Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 02, 2026 · Updated 25 times

Summary

This study tests whether theophylline, a drug used for asthma, can help people with pseudohypoparathyroidism, a rare genetic condition causing early obesity, short stature, and hormone problems. About 34 children and young adults who completed a prior trial will take the drug to see if it leads to weight loss and better hormone balance. The main focus is safety and changes in body mass index.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSEUDOHYPOPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

Conditions

Explore the condition pages connected to this study.